sciencedaily.com/releases/2...
This article is about a Cedars-Sinai study that says ADT or ATT "causes" adenocarcinoma to transform to the more aggressive neuroendocrine type in 25% of men and monitoring glutamine levels might be useful in determining if it is transforming to the neuroendocrine type.
"While glutamine is known to spur cancer growth, its role in prostate cancer cells to trigger reprogramming of adenocarcinoma cells into neuroendocrine cancer cells is a new and important finding,"
The team also examined how androgen-targeted therapy affected the cancer microenvironment.
"To our surprise, we found this type of therapy further changed the cellular environment in a way that caused adenocarcinoma cells in the prostate to transform into neuroendocrine cancer-type cells," said Bhowmick, professor of Medicine and Biomedical Sciences.
"The study raises the possibility that a simple blood test measuring glutamine might be able to pinpoint when androgen-targeted therapy is failing in a prostate cancer patient and even predict when therapy resistance will occur," said Posadas, who co-authored the study. He said the team is designing a new study to test this hypothesis.
Any insights or thoughts on this?